Table 1 Patient characteristics of the breast cancer study cohorts.
Characteristics | Training cohort | ER positive validation cohort | TNBC cohort | Neoadjuvant chemotherapy cohort |
|---|---|---|---|---|
(n = 835) | (n = 1315) | (n = 634) | (n = 1365) | |
Age, years | ||||
<=50 | 142(17.0%) | 399(30.3%) | 219(34.5%) | 668(48.9%) |
>50 | 197(23.6%) | 811(61.7%) | 312(49.2%) | 574(42.1%) |
Unknown | 496(59.4%) | 105(8.0%) | 103(16.2%) | 123(9.0%) |
Tumor size, mm | ||||
<20 | 188(22.5%) | 302(23.0%) | 73(11.5%) | 93(6.8%) |
20–50 | 146(17.5%) | 638(48.5%) | 200(31.5%) | 537(39.3%) |
>50 | 5(0.6%) | 219(16.7%) | 138(21.8%) | 507(37.1%) |
Unknown | 496(59.4%) | 156(11.9%) | 223(35.2%) | 228(16.7%) |
Lymph node status | ||||
N1 | 0(0.0%) | 174(13.2%) | 85(13.4%) | 541(39.6%) |
N2 | 0(0.0%) | 49(3.7%) | 29(4.6%) | 142(10.4%) |
N3 | 0(0.0%) | 31(2.4%) | 22(3.5%) | 95(7.0%) |
Positive but unspecified | 181(21.7%) | 455(34.6%) | 112(17.7%) | 3(0.2%) |
Negative | 654(78.3%) | 606(46.1%) | 241(38.0%) | 363(26.6%) |
Unknown | 0(0.0%) | 0(0.0%) | 145(22.9%) | 221(16.2%) |
Histological grade | ||||
Well differentiated | 91(10.9%) | 227(17.3%) | 16(2.5%) | 61(4.5%) |
Moderately differentiated | 179(21.4%) | 633(48.1%) | 67(10.6%) | 385(28.2%) |
Poorly differentiated | 67(8.0%) | 368(28.0%) | 375(59.1%) | 611(44.8%) |
Unknown | 498(59.6%) | 87(6.6%) | 176(27.8%) | 285(20.9%) |
Hormone status | ||||
ER + & PR + | 0(0.0%) | 839(63.8%) | 0(0.0%) | 448(32.8%) |
ER + & PR− | 0(0.0%) | 210(16.0%) | 0(0.0%) | 154(11.3%) |
ER- & PR + | 0(0.0%) | 0(0.0%) | 0(0.0%) | 43(32.0%) |
ER− & PR− | 0(0.0%) | 0(0.0%) | 634(100.0%) | 432(31.6%) |
Unknown | 835(100.0%) | 266(20.2%) | 0(0.0%) | 288(21.1%) |
EGFR/HER-2 status | ||||
Overexpression | 0(0.0%) | 87(6.6%) | 0(0.0%) | 262(19.2%) |
Negative | 0(0.0%) | 745(56.7%) | 634(100.0%) | 891(65.3%) |
Unknown | 835(100.0%) | 483(36.7%) | 0(0.0%) | 212(15.5%) |
Chemotherapy response | ||||
Pathological complete response | NA | 30(2.3%) | 57(9.0%) | 334(24.5%) |
Residual disease | NA | 255(19.4%) | 113(17.8%) | 1031(75.5%) |
Unknown | NA | 1030(78.3%) | 464(73.2%) | 0(0.0%) |
Years of follow-up | ||||
Median (range) | 8.3(0.0–19.1) | 5.1(0.0–17.8) | 3.1(0.0–15.8) | 2.7(0.1–7.4) |
